Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department

Christian H Nickel, Roland Bingisser, Nils G Morgenthaler

BMC Medicine · 2012 · Review

doi:10.1186/1741-7015-10-7

Abstract

The hypothalamic-pituitary-adrenal axis is activated in response to stress. One of the activated hypothalamic hormones is arginine vasopressin, a hormone involved in hemodynamics and osmoregulation. Copeptin, the C-terminal part of the arginine vasopressin precursor peptide, is a sensitive and stable surrogate marker for arginine vasopressin release. Measurement of copeptin levels has been shown to be useful in a variety of clinical scenarios, particularly as a prognostic marker in patients with acute diseases such as lower respiratory tract infection, heart disease and stroke. The measurement of copeptin levels may provide crucial information for risk stratification in a variety of clinical situations. As such, the emergency department appears to be the ideal setting for its potential use. This review summarizes the recent progress towards determining the prognostic and diagnostic value of copeptin in the emergency department.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Risk stratification is a core task in emergency medicine. Novel biomarkers such as pro-calcitonin and copeptin have emerged to assist clinicians with decision-making. Elevated pro-calcitonin levels, for example, might help to decide whether administration of antibiotics in lower respiratory tract infections is necessary.

Arginine vasopressin (AVP), also known as antidiuretic hormone, is one of the key hormones of the hypothalamic-pituitary-adrenal (HPA) axis. Copeptin, a peptide of 39 amino acids, is the C-terminal part of pro-AVP and is released together with AVP during processing of the precursor peptide (see Figure 1). Copeptin and AVP are secreted from the neurohypophysis upon hemodynamic or osmotic stimuli (see Figure 2). AVP is also involved in the endocrine stress response. Corticotropin-releasing hormone and AVP appear to have a synergistic effect, resulting in adrenocorticotropic hormone (ACTH) and cortisol release. High cortisol levels reflect a higher degree of stress, but are dependent on the integrity of the HPA-axis. Copeptin appears to be superior to cortisol in determination of the stress level, as cortisol is further downstream in the stress response, has a strong circadian rhythm and is also challenging to measure as a free hormone.

In contrast to AVP and cortisol, copeptin is stable both in serum and plasma at room temperature and can be easily measured ex vivo as a 'shadow' fragment of AVP in the circulation, in manual or fully automated chemiluminescence assays. Copeptin results are available within one hour, which is crucial for any useful biomarker in the emergency department (ED) setting.

This mini review outlines the potential prognostic and diagnostic use of copeptin in the ED in the context of a number of different possible clinical conditions and summarizes the recent progress made in this field.

Effects of copeptin and AVP in the circulation

The physiologic function of AVP is threefold. When released into the circulation, AVP mediates arteriolar vasoconstriction via the V1-receptor and exhibits an antidiuretic effect in the kidneys via the V2-receptor. A third AVP receptor appears to be involved in the secretion of ACTH. At present, it is unclear if copeptin has a physiologic effect outside the neuron, where it acts as a chaperone in the maturation process of AVP. It is noteworthy that, in vivo, the kinetics of copeptin are similar to those of AVP, whilst, ex vivo, the protein has an extraordinary stability of one to two weeks at room temperature. This favorable discrepancy allows for the precise measurement of copeptin as a surrogate marker for the unstable AVP.

Copeptin in acute myocardial infarction and heart failure

Early and safe rule-out of myocardial infarction (MI) is crucial in the ED. Reichlin et al. examined the role of copeptin in the diagnosis of 487 consecutive patients with chest pain presenting to the ED. Copeptin levels were already elevated at a time when troponin T was still undetectable (0 hours to 4 hours) in 20 out of 81 patients with the final diagnosis of acute MI. In their study, negative troponin and copeptin at the time of ED presentation was enough to rule out acute MI, with an excellent negative predictive value of 99.7%. This was confirmed in a similar study by Keller et al.. However, recent studies have shown an increased diagnostic sensitivity of high-sensitivity troponin assays compared to conventional assays in the early detection of acute MI.

At present, there is confusion on the nomenclature and clinical use of these assays. This needs to be clarified before the benefit of additional biomarkers can be fairly evaluated. First reports on a direct comparison of high-sensitivity troponin assays and copeptin confirm the additive effect, and the results of the ongoing CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction), a multicenter trial of 2000 patients with chest pain in the ED, should answer many of the open questions (ClinicalTrials.gov Identifier: NCT00952744).

In several studies, copeptin has been reported to be a useful biomarker in patients with chronic heart failure. High levels of copeptin predicted poor long-term prognosis in patients with chronic heart failure. When combined with B-type natriuretic peptide (BNP) measurement, outcome prediction could be improved further.

When copeptin was measured in 980 patients who had experienced an acute MI, it was found to be elevated in patients who died or were readmitted with heart failure, compared with survivors. Copeptin and N-terminal proBNP were independent predictors of death or heart failure at 60 days, helping to stratify patients into low-, intermediate- or high-risk groups. In a multicenter study, it was confirmed that copeptin is a strong marker for mortality and morbidity in patients with heart failure after an acute MI.

The clinical evidence in this field is increasing rapidly. A recent study of patients treated in an outpatient clinic for chronic stable heart failure showed that copeptin and high-sensitivity cardiac troponin T (hs-cTnT) levels, both single and combined, are powerful predictors of death and hospitalization. This suggests that simultaneous assessment of myocardial damage and the activated vasopressin system, through single measurement of hs-cTnT and copeptin levels, might be of prognostic relevance.

Copeptin may have not only short term prognostic relevance, but also identify patients at higher long-term risk. Increased copeptin concentrations in elderly patients with symptoms of heart failure were associated with an increased risk of all-cause mortality after a lengthy median follow-up of 13 years.

Finally, a secondary analysis from the Biomarkers in Acute Heart Failure (BACH) study looked at the interaction of copeptin and sodium concentrations. Whilst it is well known that low serum sodium is an indicator of increased mortality in patients with heart failure, no studies examined if and how the vasopressinergic system was activated. The authors of the BACH study now report significantly increased 90-day mortality, readmissions and ED visits in patients with hyponatremia, especially in those with elevated copeptin. Patients with hyponatremia and low copeptin had a lower risk. Copeptin was highly prognostic for 90-day adverse events in acute heart failure patients, adding prognostic value to clinical predictors, serum sodium and natriuretic peptides. This report is of particular interest in the light of ongoing discussions on the potential value of vasopressin receptor antagonists (such as tolvaptan) for patients with heart failure, as elevated copeptin may identify those patients with an activated AVP system most likely to benefit from AVP antagonists.

Copeptin in hyponatremia and diabetes insipidus

Hyponatremia is common in the ED, but the diagnostic approach is often challenging. In the differential diagnosis of the syndrome of inappropriate antidiuretic hormone hypersecretion and sodium depletion, copeptin showed promising results. However, a large overlap in copeptin levels still makes the differentiation between these two disorders challenging. In this context, the copeptin to urinary sodium ratio was most helpful. Further studies are needed here and currently ongoing. In other situations of disturbed water balance, such as diabetes insipidus, the role of copeptin was also investigated. Three studies showed promising results of copeptin in the differential diagnosis of polydipsia-polyuria syndrome. However, according to a recent study, the value of copeptin might be restricted to patients with no further acute illness, such as stroke or pneumonia, besides a sodium imbalance.

Copeptin as a prognostic marker

Besides the clinical indications mentioned so far, the role of copeptin as a prognostic biomarker was also examined in a variety of other indications, such as acute exacerbations of chronic obstructive pulmonary disease, lower respiratory tract infections, hemorrhagic and septic shock, stroke and traumatic brain injury. Table 1 summarizes the recent study results.

Copeptin in elderly ED patients presenting with non-specific complaints

Older patients in the ED are at risk of adverse health outcomes. Atypical disease presentation or presentation with non-specific complaints, such as weakness or fatigue, is common. The attenuated physiologic reaction of elderly patients in response to even serious illness complicates the evaluation even further. The Basel non-specific complaints (BANC) study aims to evaluate risk-stratification tools for these, mostly elderly, patients presenting to the ED with non-specific complaints. In this study, copeptin concentrations were significantly higher in non-survivors than in survivors, irrespective of the final diagnosis. Of note, the spectrum of diseases underlying non-specific complaints is extremely broad, suggesting that copeptin may well be a non-specific marker for disease severity. Copeptin was predictive of 30-day all-cause mortality and elevated levels were associated with an increased mortality in univariate models. Copeptin also provided independent and additional information to clinical risk scores, such as the Katz Index of Independence in Activities of Daily Living and the Charlson Comorbidity Index. Copeptin measurement might therefore facilitate level of care decisions in the ED for this patient group.

Copeptin and other biomarkers

In the ED, copeptin is in competition with other novel biomarkers that are also investigated for their potential use as prognosticators. Apart from established cardiac markers such as BNP, NT-proBNP and derivates of atrial natriuretic peptide, other peptides (for example mid-region pro-adrenomedullin, ST2 and growth-differentiation factor-15) are currently the focus of several research groups. The jury is still out on which markers will ultimately make it into clinical routine. The potential advantage of AVP and copeptin over these competing markers in the ED lies in its more central role as one of the key hormones in the body. It is not limited to a single organ system, but is triggered by many disease processes also outside the cardiovascular system. This non-specificity, with respect to a precise diagnostic role, is its strength as a more generalized marker for severe disturbances in patient physiology. In future head-to-head comparisons of biomarkers or biomarker panel strategies copeptin is likely to be one of the strongest candidates.

Limitations of copeptin

As with most biomarkers there are certain confounding factors for the interpretation of copeptin levels. Copeptin levels were found to be higher in the male volunteers compared with female. Especially in men, there is a strong relationship between copeptin and decreased glomerular filtration rate, probably due to decreased renal copeptin clearance. Furthermore, corticosteroids appear to inhibit copeptin release.

Conclusion

AVP is a substantial part of the endocrine stress response, resulting in ACTH and cortisol release. The trigger for the rapid release of AVP and copeptin in acute disease is not yet clear. Possibly, the body responds to acute and life-threatening diseases by immediate AVP and copeptin release. Copeptin as a biomarker appears to reflect the individual stress level.

In the ED, copeptin may be a clinically useful non-specific prognostic marker reflecting disease severity in patients with a wide array of diseases, such as lower respiratory tract infections, heart failure and stroke. Copeptin might assist with risk stratification, resource allocation and disposition planning. However, future studies are needed to evaluate ideal cut-off levels in these clinical scenarios. Additionally, intervention trials are needed to show that determination of copeptin levels in the emergency setting improves patient care.

The concept of a readily available biomarker with the ability to improve prognostic accuracy of known risk stratification tools, such as risk scores, is attractive. Is copeptin, perhaps, the long awaited biomarker that discerns 'sick' from 'not sick'?

Competing interests

BRAHMS Biomarkers, part of ThermoFisher Scientific, the manufacturer of the copeptin-assay, provided measurements for CHN and RB's study on geriatric emergency patients. No funding was obtained from commercial sources.

Authors' contributions

CHN, RB and NGM were involved in drafting and editing the manuscript. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1741-7015/10/7/prepub

References 50

  1. 1.

    Christ-Crain M Jaccard-Stolz D Bingisser R Gencay MM Huber PR Tamm M Muller B Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trialLancet2004 3639409600607

    Not in our library10.1016/s0140-6736(04)15591-8

  2. 2.

    Schuetz P Christ-Crain M Thomann R Falconnier C Wolbers M Widmer I Neidert S Fricker T Blum C Schild U Regez K Schoenenberger R Henzen C Bregenzer T Hoess C Krause M Bucher HC Zimmerli W Mueller B Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trialJAMA2009 3021010591066

    Not in our library10.1001/jama.2009.1297

  3. 3.

    Land H Schutz G Schmale H Richter D Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursorNature1982 2955847299303

    Not in our library10.1038/295299a0

  4. 4.

    Gillies GE Linton EA Lowry PJ Corticotropin releasing activity of the new CRF is potentiated several times by vasopressinNature1982 2995881355357

    Not in our library10.1038/299355a0

  5. 5.

    Rivier C Vale W Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressinNature1983 3055932325327

    Not in our library10.1038/305325a0

  6. 6.

    Rivier C Vale W Interaction of corticotropin-releasing factor and arginine vasopressin on adrenocorticotropin secretion in vivoEndocrinology1983 1133939942

    Not in our library10.1210/endo-113-3-939

  7. 7.

    Milsom SR Conaglen JV Donald RA Espiner EA Nicholls MG Livesey JH Augmentation of the response to CRF in man: relative contributions of endogenous angiotensin and vasopressinClin Endocrinol (Oxf)1985 225623629

    Not in our library10.1111/j.1365-2265.1985.tb02998.x

  8. 8.

    Schuetz P Muller B The hypothalamic-pituitary-adrenal axis in critical illnessEndocrinol Metab Clin North Am2006 354823838x

    Not in our library10.1016/j.ecl.2006.09.013

  9. 9.

    Christ-Crain M Stolz D Jutla S Couppis O Muller C Bingisser R Schuetz P Tamm M Edwards R Muller B Grossman AB Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumoniaAm J Respir Crit Care Med2007 1769913920

    Not in our library10.1164/rccm.200702-307oc

  10. 10.

    Katan M Morgenthaler N Widmer I Puder JJ Konig C Muller B Christ-Crain M Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress levelNeuro Endocrinol Lett2008 293341346

    Not in our library

  11. 11.

    Struck J Morgenthaler NG Bergmann A Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patientsPeptides2005 261225002504

    Not in our library10.1016/j.peptides.2005.04.019

  12. 12.

    Morgenthaler NG Struck J Alonso C Bergmann A Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressinClin Chem2006 521112119

    Not in our library10.1373/clinchem.2005.060038

  13. 13.

    Birnbaumer M Vasopressin receptorsTrends Endocrinol Metab2000 1110406410

    Not in our library10.1016/s1043-2760(00)00304-0

  14. 14.

    Thibonnier M Preston JA Dulin N Wilkins PL Berti-Mattera LN Mattera R The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathwaysEndocrinology1997 1381041094122

    Not in our library10.1210/en.138.10.4109

  15. 15.

    Morgenthaler NG Muller B Struck J Bergmann A Redl H Christ-Crain M Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shockShock2007 282219226

    Not in our library10.1097/shk.0b013e318033e5da

  16. 16.

    Reichlin T Hochholzer W Stelzig C Laule K Freidank H Morgenthaler NG Bergmann A Potocki M Noveanu M Breidthardt T Christ A Boldanova T Merki R Schaub N Bingisser R Christ M Mueller C Incremental value of copeptin for rapid rule out of acute myocardial infarctionJ Am Coll Cardiol2009 5416068

    Not in our library10.1016/j.jacc.2009.01.076

  17. 17.

    Keller T Tzikas S Zeller T Czyz E Lillpopp L Ojeda FM Roth A Bickel C Baldus S Sinning CR Wild PS Lubos E Peetz D Kunde J Hartmann O Bergmann A Post F Lackner KJ Genth-Zotz S Nicaud V Tiret L Munzel TF Blankenberg S Copeptin improves early diagnosis of acute myocardial infarctionJ Am Coll Cardiol2010 551920962106

    Not in our library10.1016/j.jacc.2010.01.029

  18. 18.

    Reichlin T Hochholzer W Bassetti S Steuer S Stelzig C Hartwiger S Biedert S Schaub N Buerge C Potocki M Noveanu M Breidthardt T Twerenbold R Winkler K Bingisser R Mueller C Early diagnosis of myocardial infarction with sensitive cardiac troponin assaysN Engl J Med2009 3619858867

    Not in our library10.1056/nejmoa0900428

  19. 19.

    Keller T Zeller T Peetz D Tzikas S Roth A Czyz E Bickel C Baldus S Warnholtz A Frohlich M Sinning CR Eleftheriadis MS Wild PS Schnabel RB Lubos E Jachmann N Genth-Zotz S Post F Nicaud V Tiret L Lackner KJ Munzel TF Blankenberg S Sensitive troponin I assay in early diagnosis of acute myocardial infarctionN Engl J Med2009 3619868877

    Not in our library10.1056/nejmoa0903515

  20. 20.

    Jaffe AS Apple FS High-sensitivity cardiac troponin: hype, help, and realityClin Chem563342344

    Not in our library10.1373/clinchem.2009.136218

  21. 21.

    Giannitsis E Kehayova T Vafaie M Katus HA Combined testing of high-sensitivity troponin T and copeptin on presentation at prespecified cutoffs improves rapid rule-out of non-ST-segment elevation myocardial infarctionClin Chem2011 571014521455

    Not in our library10.1373/clinchem.2010.161265

  22. 22.

    Stoiser B Mortl D Hulsmann M Berger R Struck J Morgenthaler NG Bergmann A Pacher R Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failureEur J Clin Invest2006 3611771778

    Not in our library10.1111/j.1365-2362.2006.01724.x

  23. 23.

    Gegenhuber A Struck J Dieplinger B Poelz W Pacher R Morgenthaler NG Bergmann A Haltmayer M Mueller T Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failureJ Card Fail2007 1314249

    Not in our library10.1016/j.cardfail.2006.09.004

  24. 24.

    Khan SQ Dhillon OS O'Brien RJ Struck J Quinn PA Morgenthaler NG Squire IB Davies JE Bergmann A Ng LL C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) studyCirculation2007 1151621032110

    Not in our library10.1161/circulationaha.106.685503

  25. 25.

    Voors AA von Haehling S Anker SD Hillege HL Struck J Hartmann O Bergmann A Squire I van Veldhuisen DJ Dickstein K C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL studyEur Heart J2009 301011871194

    Not in our library10.1093/eurheartj/ehp098

  26. 26.

    Tentzeris I Jarai R Farhan S Perkmann T Schwarz MA Jakl G Wojta J Huber K Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failureEur J Heart Fail2011 137726733

    Not in our library10.1093/eurjhf/hfr049

  27. 27.

    Alehagen U Dahlstrom U Rehfeld JF Goetze JP Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failureJAMA2011 3052020882095

    Not in our library10.1001/jama.2011.666

  28. 28.

    Maisel A Xue Y Shah K Mueller C Nowak R Peacock WF Ponikowski P Mockel M Hogan C Wu AH Richards M Clopton P Filippatos GS Di Somma S Anand I Ng L Daniels LB Neath SX Christenson R Potocki M McCord J Terracciano G Kremastinos D Hartmann O von Haehling S Bergmann A Morgenthaler NG Anker SD Increased 90-Day mortality in acute heart failure patients with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) StudyCirc Heart Fail2011 45613620

    Not in our library10.1161/circheartfailure.110.960096

  29. 29.

    Vachharajani TJ Zaman F Abreo KD Hyponatremia in critically ill patientsJ Intensive Care Med2003 18138

    Not in our library10.1177/0885066602239119

  30. 30.

    Fenske W Stork S Blechschmidt A Maier SG Morgenthaler NG Allolio B Copeptin in the differential diagnosis of hyponatremiaJ Clin Endocrinol Metab2009 941123129

    Not in our library10.1210/jc.2008-1426

  31. 31.

    Fenske W Quinkler M Lorenz D Zopf K Haagen U Papassotiriou J Pfeiffer AF Fassnacht M Stork S Allolio B Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome--revisiting the direct and indirect water deprivation testsJ Clin Endocrinol Metab2011 96515061515

    Not in our library10.1210/jc.2010-2345

  32. 32.

    Katan M Morgenthaler NG Dixit KC Rutishauser J Brabant GE Muller B Christ-Crain M Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assayJ Clin Endocrinol Metab2007 92726402643

    Not in our library10.1210/jc.2006-2046

  33. 33.

    Nigro N Muller B Morgenthaler NG Fluri F Schutz P Neidert S Stolz D Bingisser R Tamm M Christ-Crain M Katan M The use of copeptin, the stable peptide of the vasopressin precursor, in the differential diagnosis of sodium imbalance in patients with acute diseasesSwiss Med Wkly2011 141w13270

    Not in our library10.4414/smw.2011.13270

  34. 34.

    Stolz D Christ-Crain M Morgenthaler NG Leuppi J Miedinger D Bingisser R Muller C Struck J Muller B Tamm M Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPDChest2007 131410581067

    Not in our library10.1378/chest.06-2336

  35. 35.

    Muller B Morgenthaler N Stolz D Schuetz P Muller C Bingisser R Bergmann A Tamm M Christ-Crain M Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infectionsEur J Clin Invest2007 372145152

    Not in our library10.1111/j.1365-2362.2007.01762.x

  36. 36.

    Katan M Nigro N Fluri F Schuetz P Morgenthaler NG Jax F Meckel S Gass A Bingisser R Steck A Kappos L Engelter S Muller B Christ-Crain M Stress hormones predict cerebrovascular re-events after transient ischemic attacksNeurology2011 766563566

    Not in our library10.1212/wnl.0b013e31820b75e6

  37. 37.

    Urwyler SA Schuetz P Fluri F Morgenthaler NG Zweifel C Bergmann A Bingisser R Kappos L Steck A Engelter S Muller B Christ-Crain M Katan M Prognostic value of copeptin: one-year outcome in patients with acute strokeStroke2010 41715641567

    Not in our library10.1161/strokeaha.110.584649

  38. 38.

    Dong XQ Huang M Yang SB Yu WH Zhang ZY Copeptin is associated with mortality in patients with traumatic brain injuryJ Trauma2011 71511941198

    Not in our library10.1097/ta.0b013e31821283f2

  39. 39.

    Aminzadeh F Dalziel WB Older adults in the emergency department: a systematic review of patterns of use, adverse outcomes, and effectiveness of interventionsAnn Emerg Med2002 393238247

    Not in our library10.1067/mem.2002.121523

  40. 40.

    Nemec M Koller MT Nickel CH Maile S Winterhalder C Karrer C Laifer G Bingisser R Patients presenting to the emergency department with non-specific complaints: the Basel Non-specific Complaints (BANC) studyAcad Emerg Med2010 173284292

    Not in our library10.1111/j.1553-2712.2009.00658.x

  41. 41.

    Nickel CH Ruedinger J Misch F Blume K Maile S Schulte J Kohrle J Hartmann O Giersdorf S Bingisser R Copeptin and peroxiredoxin-4 independently predict mortality in patients with nonspecific complaints presenting to the emergency departmentAcad Emerg Med2011 188851859

    Not in our library10.1111/j.1553-2712.2011.01126.x

  42. 42.

    Nickel CH Nemec M Bingisser R Weakness as presenting symptom in the emergency departmentSwiss Med Wkly2009 13917-18271272

    Not in our library10.4414/smw.2009.12620

  43. 43.

    Maisel A Mueller C Nowak R Peacock WF Landsberg JW Ponikowski P Mockel M Hogan C Wu AH Richards M Clopton P Filippatos GS Di Somma S Anand I Ng L Daniels LB Neath SX Christenson R Potocki M McCord J Terracciano G Kremastinos D Hartmann O von Haehling S Bergmann A Morgenthaler NG Anker SD Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trialJ Am Coll Cardiol2010 551920622076

    Not in our library10.1016/j.jacc.2010.02.025

  44. 44.

    Peacock WF Nowak R Christenson R DiSomma S Neath SX Hartmann O Mueller C Ponikowski P Mockel M Hogan C Wu AH Richards M Filippatos GS Anand I Ng LL Daniels LB Morgenthaler N Anker SD Maisel AS Short-term mortality risk in emergency department acute heart failureAcad Emerg Med2011 189947958

    Not in our library10.1111/j.1553-2712.2011.01150.x

  45. 45.

    Januzzi JL Jr Peacock WF Maisel AS Chae CU Jesse RL Baggish AL O'Donoghue M Sakhuja R Chen AA van Kimmenade RR Lewandrowski KB Lloyd-Jones DM Wu AH Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) studyJ Am Coll Cardiol2007 507607613

    Not in our library10.1016/j.jacc.2007.05.014

  46. 46.

    Wollert KC Kempf T Peter T Olofsson S James S Johnston N Lindahl B Horn-Wichmann R Brabant G Simoons ML Armstrong PW Califf RM Drexler H Wallentin L Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndromeCirculation2007 1158962971

    Not in our library10.1161/circulationaha.106.650846

  47. 47.

    Bhandari SS Loke I Davies JE Squire IB Struck J Ng LL Gender and renal function influence plasma levels of copeptin in healthy individualsClin Sci (Lond)2009 1163257263

    Not in our library10.1042/cs20080140

  48. 48.

    de Kruif MD Lemaire LC Giebelen IA Struck J Morgenthaler NG Papassotiriou J Elliott PJ van der Poll T The influence of corticosteroids on the release of novel biomarkers in human endotoxemiaIntensive Care Med2008 343518522

    Not in our library10.1007/s00134-007-0955-x

  49. 49.

    Katan M Fluri F Morgenthaler NG Schuetz P Zweifel C Bingisser R Muller K Meckel S Gass A Kappos L Steck AJ Engelter ST Muller B Christ-Crain M Copeptin: a novel, independent prognostic marker in patients with ischemic strokeAnn Neurol2009 666799808

    Not in our library10.1002/ana.21783

  50. 50.

    Zweifel C Katan M Schuetz P Siegemund M Morgenthaler NG Merlo A Mueller B Christ-Crain M Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhageBMC Neurol2010 1034

    Not in our library10.1186/1471-2377-10-34

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.